Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Norcantharidin Lipid Microsphere in Solid Tumors
NCT04673396Phase 1Unknown
- Sponsor
- Beijing Nuokangda Pharmaceutical Technology
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Norcantharidin Lipid Microsphere for Injection in solid tumor (3 arms), sponsored by Beijing Nuokangda Pharmaceutical Technology. Primary endpoints: Peak Plasma Concentration (Cmax), Area Under the Curve from time 0 to time t and 1 more. Status: unknown.
02
Drugs
Norcantharidin Lipid Microsphere for Injection
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04673396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673396.